Should you buy or sell Majestic Wines plc, Enquest plc and Hikma Pharmaceuticals plc after today’s news?

Roland Head takes a closer look at today’s news from Majestic Wines plc (LON:WINE), Enquest plc (LON:ENQ) and Hikma Pharmaceuticals plc (LON:HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares of Majestic Wines (LSE: WINE) moved 5% higher in the first half hour of trading this morning, after the wine retailer said that sales rose by 41.3% to £402.1m last year.

The increase is mostly the result of last year’s acquisition of online start-up Naked Wines, where sales hit £100m for the first time last year. Like-for-like-sales from Majestic’s retail stores rose by a more modest 4.8% — although this was the first increase for four years.

However, last year’s growth came at a price. Majestic’s adjusted pre-tax profit fell by 30% to £15m in 2015/16. The group says that this is the result of IT upgrades and acquisition costs. A new dividend policy targeting a payout of 35% of adjusted earnings is due to start this year.

The message from Majestic today is that investment in marketing and technology will deliver long-term benefits. I’m tempted to agree. Today’s results look reasonable and the firm’s 2019 sales target of £500m seems achievable.

However, at 460p, Majestic trades on a 2017 forecast P/E of 27. I’d wait for the next dip down before buying.

Oil bankruptcy risk?

North Sea oil operator Enquest (LSE: ENQ) climbed 12% this morning after issuing a statement denying a weekend report in The Telegraph. The article suggested Enquest may be in discussions with the North Sea regulator regarding bankruptcy plans.

Enquest is the operator and lead developer of the Kraken project, which is due to start producing oil next year. But the group has net debt of $1.63bn and is expected to report an increased loss of $68m in 2017 after its current hedging provisions expire at the end of this year. If oil prices remain under $60, then as things stand Enquest could see a notable reduction in cash flow in 2017.

In my view, Enquest’s high debt levels represent a big risk to equity investors. There’s still a real possibility that the firm will have to raise cash by issuing new shares. This could be highly dilutive for shareholders.

In my view, there are better options elsewhere in the oil sector.

Should you follow director dealing?

Shares of Hikma Pharmaceuticals (LSE: HIK) have risen by 126% over the last three years. They’re currently within 15% of last year’s all-time high of 2,520p. Given this strong performance, it’s interesting to note that at least one key director, chairman and chief executive officer Said Darwazah, is still bullish on the stock.

Mr Darwazah spent £1.52m on Hikma shares last week, increasing his stake in the firm to 5.55%. Although the purchase is small relative to the £289m value of Mr Darwazah’s total holding, it looks positive to me.

Hikma’s adjusted earnings per share are expected to fall 12% to $1.24 this year, before rising by 35% to $1.68 per share in 2017. The firm’s current share price of 2,179p puts the stock on a 2017 forecast P/E of 18 and gives Hikma a forecast PEG ratio of 0.8.

The PEG — or price-to-earnings growth ratio — was a favoured indicator of legendary growth investor Jim Slater. Shares with a PEG ratio of less than one were said to be attractively priced. Analysts rate Hikma as a buy or a strong buy. I believe Hikma could deliver further gains from current levels.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Majestic Wine. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »